To evaluate the effects of low-dose growth hormone (GH) therapy combined with diet restriction on changes in body composition and the consequent change in insulin resistance in newly-diagnosed obese type 2 diabetic patients. DESIGN: Double-blind and placebo-controlled trial of 25-kcalakg IBW diet daily with GH (n 9; rhGH, 0.15 IUakg body weightaweek) or placebo (n 9) for 12 weeks. SUBJECTS: Eighteen newly-diagnosed obese type 2 diabetic patients (age 42 ± 56 y, body mass index 28.1 AE 2.7 kgam 2 ). MEASUREMENTS: Body composition and fat distribution parameters (by bioelectrical impedance analyzer and CT scans), serum IGF-1; serum glucose, insulin and free fatty acid (FFA) during oral glucose tolerance test (OGTT); HbA 1c ; serum lipid pro®les; and glucose disposal rate (GDR) by euglycemic hyperinsulinemic clamp at baseline and after treatment. RESULTS: The fraction of body weight lost as fat lost was signi®cantly greater (0.98 AE 0.39 vs 0.52 AE 0.32 kgakg, P`0.05) and visceral fat area was decreased more in the GH-treated group compared to the placebo-treated group (27.9 vs 21.6%, P`0.05). Lean body mass and muscle area were reduced in the placebo-treated group, whereas an increase in both was observed in the GH-treated group. GDR the was signi®cantly increased in only the GH-treated group (4.67 AE 1.05 vs 6.95 AE 0.91 mgakgamin, P`0.05). The GH-induced increase in GDR was positively correlated with the decrease in the ratio of visceral fat areaamuscle area (r 0.588, P 0.001). Serum glucose levels and insulin-and FFA-area under the curve during OGTT and HbA 1c were signi®cantly decreased after GH treatment. LDL-cholesterol level was decreased in only the GH-treated group. CONCLUSION: Low-dose GH treatment combined with dietary restriction resulted not only in a decrease of visceral fat but also in an increase of muscle mass with a consequent improvement of the insulin resistance observed in obese type 2 diabetic patients.
Introduction
Insulin resistance is frequently observed in obese subjects and constitutes an independent risk factor for the development of type 2 diabetes mellitus (DM). 1 In particular, an increase in visceral adiposity accounts for most of the abnormal metabolic pathways predisposing to type 2 DM, including marked peripheral insulin resistance. 2, 3 Considering that skeletal muscle is the primary tissue responsible for glucose uptake, 4, 5 an increase in skeletal muscle mass may bene®cially in¯uence insulin sensitivity via its capacity to uptake a glucose load. Therefore, the most effective means to improve insulin sensitivity in obese type 2 diabetic patients would be a regimen that could accelerate visceral fat loss and conserve or increase lean body mass.
With increased adiposity, physiologic growth hormone (GH) secretion is impaired and the GH responses to all stimuli are decreased. 6, 7 Decreased secretion of GH in obesity, therefore, results in a loss of the lipolytic effect of GH and also loss of the ability of GH to abrogate the antilipolytic actions of hyperinsulinemia associated with obesity. 8 Diet restriction as a basic treatment for obesity is complicated by protein catabolism associated with undesirable loss of skeletal muscle mass. 9 GH retains a positive nitrogen balance during dietary restriction by increasing insulin-like growth factor (IGF)-1, a peptide that is proposed to mediate the anabolic effects of GH. 10, 11 However, higher doses and longer duration of GH treatment can lead to a substantial impairment of both hepatic and peripheral insulin sensitivity, which may result in hyperinsulinemia. 12 ± 15 Although additive to the anabolic actions of GH, hyperinsulinemia abrogates the lipolytic actions of GH due to lipogenesis stimulated by insulin. In our previous study, 16 we demonstrated that in obese subjects fed a hypocaloric diet, GH administration accelerates body fat loss, exerts anabolic effects and improves GH secretion.
In this study, we have investigated whether low-dose GH therapy combined with diet restriction could play a possible therapeutic role in improving insulin sensitivity in obese type 2 diabetic patients.
Methods

Subjects
Eighteen obese Koreans who were newly diagnosed type 2 DM according to results of a 75 g oral glucose tolerance test (OGTT) participated in this study. All of them were mildly type 2 diabetic based on their baseline levels of HbA 1c , ranging from 5.9 to 7.1% (6.3 AE 1.3%). All were 20% over ideal body weight (IBW) and ranged in age from 42 to 56 y ( Table 1) . The criteria for exclusion from the study were diabetic microangiopathy, previous cardiovascular events, hypertension or any form of cardiac disease. None had used any hormonal preparations or drugs within 60 days prior to commencement of the study. The study was approved by the hospital ethics committee and informed consent was obtained from each subject.
Study protocol
The study was a 12 week, randomized, double-blind, placebo-controlled trial of the administration of human GH (Eutropin, LG, Seoul, Korea). The daily dose of GH (9 mgakg BW: 0.15 IUakg BWaweek) was administered subcutaneously before bedtime six times a week excluding Sunday. The placebo vials contained the same vehicle as the GH vials and both preparations were visually indistinguishable. Compliance was assessed by counting the returned empty vials. The subjects were studied as outpatients. After all examinations, subjects were instructed to maintain a daily diet of 25 kcalakg IBW with 1.2 g proteinakg IBW. Subjects maintained their routine activities. They were also instructed by a dietician how to maintain their diet and to record their daily intake and activities in a booklet provided to them. The diet records were reviewed for accuracy with the subjects by a dietician. The energy value and nutrient content of daily dietary intakes were calculated using a standard computer program.
17 Subjects were allowed an adaptation period of 1 week prior to treatment. After this period, subjects were randomly assigned to receive either GH or placebo. During the 12 week treatment period and 1 week after the last injection, subjects were seen by a dietician weekly and dietary intakes were monitored. Diet compliance by study subjects was excellent. The two groups had similar means of daily energy intake (GH-treated, 25.9 AE 2.1 kcalakg IBW; placebo-treated, 25.6 AE 3.1 kcalakg IBW) and protein intake (GH-treated, 1.19 AE 0.74 gakg IBW; placebo-treated, 1.21 AE 0.96 gakg IBW) for 13 weeks.
Body weight and height were measured in the morning, unclothed without shoes. The body mass index (BMI) was calculated as body weight in kilograms divided by height in meters squared. Waist circumference was measured with ā exible plastic tape midway between the lower rib margin and the iliac crest, and the hip girth was measured at the widest part of the hip. Both circumferences were measured in the standing position after normal expiration.
Body composition was determined by a bioelectrical impedance analyzer (Biodynamics Model 400, Bellevue, WA, 12.0 VDC, 0.5A). CT scans were performed (Philips, Tomoscan 350, Mahway, NJ) to measure visceral and subcutaneous fat areas at the level of the umbilicus and the muscle area and fat area at the mid-thigh level (midportion of the upper border of the patella and greater trochanter). Adipose tissue was de®ned at a density of 7150 to 750 Houns®eld units (HU) and muscle tissue was de®ned at a density of 749 to 100 HU. 18 Blood samples were taken at 08:00 h after fasting from midnight on each Monday at baseline, 4 weeks, 8 weeks and 12 weeks after commencing treatment and also 1 week later after ending treatment for measurement of fasting glucose, insulin and free fatty acid (FFA) levels. Subjects underwent a 75 g OGTT after a 10 ± 12 h overnight fast before and two days after the last injection. Blood was subsequently collected at 0, 60 and 120 min to determine serum glucose, insulin and FFA levels.
Four days later after the last injection an euglycemic, hyperinsulinemic glucose clamp was performed after an overnight fast, as previously described. 19 The glucose disposal 
Analytical methods
The serum glucose level was measured by the glucoseoxidase method. The insulin level was measured by an enzyme-linked immunoabsorbent assay (ELISA). This ELISA uses two monoclonal antibodies (Novo, Nordisk AaS, Denmark) directed against human insulin and does not crossreact with human proinsulin. Serum FFA concentrations were determined by colorimetric method. IGF-1 was measured by an IRMA kit (Diagnostic System Laboratories, Webster, TX, USA) and the sensitivity was 0.3 mgal. Its intra-and inter-assay coef®cients of variation were less than 10%.
Statistical methods
The total area under the curve (AUC) was calculated by the trapezoidal method. The results were expressed as the mean AE s.e.m. Non-parametric Wilcoxon's rank sum test for paired data was used to compare values before and after treatment in each group.
Comparison was made using the Mann ± Whitney U-test between the GH-treated group and the placebo-treated group. Signi®cance of the correlation was examined using the non-parametric Spearman's rank correlation test. P`0.05 was accepted as the level of signi®cance.
Results
The two groups were matched with regard to sex and age. At baseline, the two groups did not differ in IBW, BMI or waistto-hip ratio ( Table 1) .
Effect of GH administration on weight loss and body composition
The mean total body weight loss during the entire study was equivalent in both groups. Body weight decreased by 4.7 AE 1.0 kg (5.7 AE 1.3% of initial body weight) and 5.2 AE 1.3 kg (6.4 AE 3.5%) during placebo and GH treatment, respectively. The fraction of body weight lost as fat lost was signi®cantly greater in the GH-treated group than in the placebo group (GH-treated, 0.98 AE 0.39 kgakg vs placebo-treated, 0.52 AE 0.32 kgakg, P`0.05). Lean body mass (LBM) as measured by impedence in the placebo group declined whereas GH treatment increased LBM (GH-treated, 0.45 AE 1.87 kg, vs placebo-treated, 71.21 AE 1.311 kg, P`0.05, Table 2 ). The changes in TBW determined by impedence during treatment were insigni®cant and they were similar between both groups (GH-treated 0.15% vs placebo-treated 0.10%). GH treatment resulted in a signi®cant decrease in the visceral fat area (GH-treated, 27.9% vs placebo-treated, 21 .6% compared to baseline values, P`0.05) and in the fraction of body weight lost as visceral fat area lost (GH-treated, 6.45 AE 3.27 cm 2 akg vs placebo-treated, 2.69 AE 3.20 cm 2 akg, P`0.05, Figure 1 ). Concommitantly, GH treatment resulted in an increase in the muscle area as determined by CT scan at the mid-thigh level (GH-treated, 2.53 AE 1.32 cm 2 vs placebo-treated, 73.03 AE 4.31, P`0.05). The ratio of visceral fat areaamuscle area (VMR) was signi®cantly decreased in both groups after the treatment period, although it was lower in the GH-treated group compared to the placebo group (GHtreated, 0.72 AE 0.08 vs placebo-treated, 0.83 AE 0.14, P`0.05, Table 2 ).
Glucose metabolism
Fasting glucose levels tended to decrease in both groups during the treatment period, but decreased signi®cantly after 12 weeks of treatment compared to baseline only in the GH-treated group (Figure 2 ). Fasting insulin levels showed a small, but nonsigni®cant increase at 4 weeks in the GH-treated group. After 8 and 12 weeks of treatment fasting insulin and FFA levels were lower in the GH group GH treatment in obese type 2 DM SY Nam et al compared to the placebo group, but the decreased levels were not of statistical signi®cance. There were signi®cant decreases in fasting insulin and FFA levels between baseline and after 12 weeks of treatment in both groups (Figure 2 ). There were no signi®cant changes in glucose, insulin and FFA levels at 13 weeks (1 week after the last injection), compared to 12 weeks (Figure 2 ). The glucose, insulin and FFA area under the curve (AUC) during OGTT decreased more in the GH-treated group than in the placebo group (P`0.05, Table 3 ). There was a positive correlation between changes in FFA-AUC and visceral fat loss (r 0.560, P 0.016). The level of HbA 1c was signi®cantly decreased after GH treatment (P`0.05, Table 3 ). The baseline GDR values were negatively correlated with visceral fat area (r 70.78, P`0.001) and with VMR in both group (r 70.784, P`0.001). After treatment, the GH group exhibited a signi®cantly higher GDR than the placebo group (GH-treated, 6.95 AE 0.91 mgakg min vs placebotreated, 4.67 AE 1.05 mgakg min, P`0.05, Figure 3 ). The GH treatment-stimulated increase in GDR was positively correlated with the change in FFA-AUC (r 0.725, P`0.001) and the change in VMR (r 0.588, P 0.001). Insulin-mediated glucose uptake, as estimated from the MaI ratio, was also signi®cantly increased in GH-treated group (5.7 AE 1.0 mgakg min per mUal Â 100) compared placebo group (4.1 AE 0.9 mgakg min per mUal Â 100, P`0.05, Table 3 ).
IGF-1 levels and lipid pro®les
GH treatment resulted in a 1.6-fold increase in IGF-1 despite caloric restriction (Table 4) . Total cholesterol and triglyceride levels were decreased in both groups after treatment, whereas LDL-cholesterol level was decreased in only the GH group (Table 4) .
Side effects
No drop-outs from either treatment group occurred during the course of the study. Side effects were observed in ®ve subjects in the GH group. Three subjects had slight peripheral edema and two complained of arthralgia. The side effects appeared during the second week of treatment and subsided spontaneously. In the placebo group, one subject also experienced slight and transient edema.
Discussion
We have demonstrated here that low-dose GH treatment combined with dietary restriction, resulted in a decrease in visceral fat and an increase in muscle mass with a consequent improvement of the insulin resistance in obese patients with type 2 DM.
Although the mean total body weight loss during the entire study was equivalent in both groups subject to diet restriction, GH treatment resulted in a 1.8-fold increase in the fraction of body weight lost as fat lost and also a greater loss of visceral fat compared to treatment with placebo. Considering the well documented lipolytic effect of GH, 20, 21 the ®nding of a preferential reduction in visceral { P`0.05 placebo group vs GH group after treatment.
GH treatment in obese type 2 DM SY Nam et al fat deposits observed in our study is consistent with the report demonstrating that the GH-stimulated abrogation in the antilipolytic effects of insulin is selective for speci®c adipose tissue deposits. 22 GH treatment causes salt and water retention, 23 which may complicate interpretation of changes in body weight and lean body mass measured by bioelectrical impedence. However the increase in total body water (TBW) content occurs within 4 ± 6 weeks after the start of GH administration and thereafter any further changes are negligible. 24 This is consistent with our ®nding that GHinduced change in TBW content was insigni®cant.
All of our subjects who had more than 100 cm 2 of visceral fat area were designated as exhibiting visceral fat obesity. 25 They were newly diagnosed with type 2 DM with slightly elevated HbA 1c levels and all demonstrated prominent insulin resistance, as judged from GDR values measured during the euglycemic hyperinsulinemic glucose clamp study. Visceral fat tissue is characterized by its high lipogenic activity as well as its accelerated lipolytic activity. The consequent high circulating level of FFA has been considered to be the principal factor in insulin resistance. 25 ± 28 Consistent with the demonstrated association between visceral adiposity and insulin resistance, 29, 30 baseline GDR values were negatively correlated with visceral fat area in this study.
One of the striking ®ndings of our study was that GH treatment resulted in a small, but nonsigni®cant increase in insulin levels at 4 weeks, whereas insulin levels were decreased at 8 weeks and signi®cantly decreased at 12 weeks compared to pretreatment baseline levels. These ®nd-ings contrast with previous studies reporting that GH treatment reduced insulin sensitivity and consequently induced a signi®cant hyperinsulinemia. 31 ± 34 This discrepancy could be explained by the dose and duration of GH therapy as well as the degree of diet restriction. A signi®cant increase in the fasting insulin level has been reported in obese patients receiving high dose GH (1 IUakg IBWaweek) for 4 weeks while on a severely hypocaloric diet (10 kcalakg IBWaday). 31 These authors also did not observe that GH treatment could enhance diet-induced fat mass reduction. Relatively high Figure 3 Glucose disposal rate (GDR) during hyperinsulinemic euglycemic clamp test before and after 12 weeks of placebo and GH treatment. *P`0.05 before vs after treatment in each group. { P`0.05 placebo group vs GH group after treatment.
GH treatment in obese type 2 DM SY Nam et al doses of GH induce hyperinsulinemia, which may antagonize the lipolytic effects of GH. Snyder et al 11 observed that a higher dose of GH increased urinary excretion of c-peptide and that there was an inverse correlation between the degree of fat loss and urinary c-peptide excretion during GH treatment. In this study, insulin-AUC during OGTT decreased more in the GH group than in the placebo group. This is discordant with our previous result describing that GH treatment did not alter the level of insulin-AUC during OGTT when the same dose of GH was administered as in the present study. 16 This contradictory ®nding may be associated with the timing of test: OGTT was performed within 12 h after the last injection in our previous study 16 and in this study it was performed over 36 h after the last injection. This is consistent with the known detrimental effect of acute GH administration on postreceptor insulin action at the level of liver and peripherally in normal man after 12 h. 12, 13 This contention is also supported by the fact that the fasting insulin level at 12 weeks did not differ from that at 13 weeks (1 week after the last injection).
O'Neal et al 32 have reported that administration of a relatively low dose of GH (0.24 IUakg BWaweek) persistently elevated fasting insulin and c-peptide levels despite GDR returning to pretreatment values by 3 months of GH treatment in GH-de®cient adults. Johannsson et al 33 have demonstrated that 6 weeks of low dose GH (0.2 IUakg BWaweek) treatment in obese men resulted in a temporary decrease in GDR, that after 6 months of treatment was restored to baseline levels, but after 9 months an improvement was found. In contrast, our observation of a marked improvement in the GDR to 12 weeks of GH treatment was unexpected. This rapid improvement could be explained by the relatively lower dose of GH used in this study and by the dietary restriction.
Alternatively, considering that skeletal muscle is the primary tissue responsible for glucose uptake, 4,5 sparing of LBM by GH treatment despite caloric restricition also may explain the increased GDR observed in this study. This ®nding is concordant with the improvement of nitrogen balance observed in our previous study 16 and in other studies 10, 11, 27, 36 of energy-restricted obese patients treated with GH, demonstrating that the anabolic effects of GH are retained even when energy intake is reduced. We observed here that the baseline GDR was negatively correlated with baseline VMR and that the decrease in VMR was positively correlated with the increase in GDR after GH treatment. These ®ndings suggest that GH treatment resulted not only in a reduction in visceral fat but also in an increase in muscle mass, which could be synergistic to improve insulin sensitivity. In addition, the reported effect of GH to increase glucose transport together with an increase in the proportion of insulin-sensitive type I muscle ®bers 37 and an increased level of IGF-1 with its insulin-like effect 38 may have contributed to the overall improvement in GDR.
Consistent with the ability of GH to stimulate hepatic LDL-receptor activity, 39, 40 LDL-cholesterol level decreased more in the GH group than in the placebo group. The reduction in total cholesterol observed is conceivably therefore a consequence of a decrease in LDL-cholesterol in the GH group.
In conclusion, we have demonstrated that low-dose GH treatment combined with dietary restriction resulted not only in a decrease of visceral fat but also in an increase of muscle mass with a consequent improvement of the insulin resistance observed in obese type 2 diabetic patients.
